⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LLY News
Eli Lilly & Co.
AMERICAN WRITERS MUSEUM’S NEW SPECIAL EXHIBIT AMERICAN PROPHETS: WRITERS, RELIGION, AND CULTURE NOW OPEN THROUGH NOVEMBER 2026
globenewswire.com
LLY
Ability Biotherapeutics nomme Angèle Maki, Ph. D., au poste de cheffe de la direction commerciale
businesswire.com
BMY
GENK
MRK
LLY
Pirtobrutinib Outperforms Bendamustine Plus Rituximab for Previously Untreated CLL/SLL
prnewswire.com
LLY
Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
prnewswire.com
LLY
Lilly declares first-quarter 2026 dividend
prnewswire.com
LLY
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AMGN
PFE
LLY
AZN
BMY
NVS
SNY
GSK
UCB
ARQT
REGN
INCY
ABBV
BIIB
MRK
JNJ
VNDA
RAPT
CHAI
ONON
ION
ASMB
CRVS
APG
KSCP
KYMR
XBI
IBB
ADSK
CDNS
SNPS
Neuroblastoma Market - A Global and Regional Analysis: Focus on Treatment and Regional Analysis - Analysis and Forecast, 2025-2035
globenewswire.com
NVS
LLY
Carolyn Bertozzi returns to Lilly board of directors
prnewswire.com
LLY
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia
globenewswire.com
AMZN
LLY
Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
prnewswire.com
LLY